ARTICLE | Company News
Avid Therapeutics deal
March 14, 1994 8:00 AM UTC
Avid (Philadelphia) obtained an option from Emory University for exclusive worldwide rights to license several hundred non-nucleoside compounds to be evaluated using Avid's hepatitis B and hepatitis C...